AmyriAD to Present Clinical and Preclinical Data at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Los Angeles, CA, November 29, 2022 – AmyriAD Therapeutics (AmyriAD) a privately held, late clinical-stage pharmaceutical development company focused on advancing therapies for Alzheimer’s disease (AD), today announced that it will present data on their lead candidate AD101 at the 15th Clinical Trials on Alzheimer’s Disease Conference (CTAD) on November 29 – December 2 in…